The startup develops targeted pharmacological therapies for treating substance use disorders, utilizing evidence-based approaches to enhance patient adherence and recovery outcomes. By addressing the barriers to effective treatment, the company enables individuals struggling with addiction to achieve sustainable recovery and improved quality of life.
Funding
$11.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Substance use disorders affect millions, yet a significant treatment gap exists due to limited therapeutic options and challenges in patient adherence. Current treatments often fail to address the underlying neurobiological mechanisms of addiction, leading to high relapse rates. There are no FDA-approved medications for stimulant use disorders like cocaine use disorder.
Solution
Tempero Bio is a clinical-stage biopharmaceutical company developing targeted pharmacological therapies to treat substance use disorders by modulating glutamate signaling in the brain. Their lead drug candidate, TMP-301, is a potent, orally-available, metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) being investigated for cocaine and alcohol use disorders. TMP-301 is designed to reduce excessive glutamate signaling, a key factor in addiction, and has shown promise in preclinical studies. By addressing the neurobiological basis of addiction, Tempero Bio aims to provide more effective treatments that reduce relapse rates and improve patient outcomes.
Target Audience
The primary target audience includes individuals with substance use disorders, particularly cocaine and alcohol use disorders, and the healthcare providers who treat them.
Features
- TMP-301: A selective mGluR5 negative allosteric modulator (NAM) designed to dampen, but not block, glutamate signaling in specific brain regions associated with substance abuse.
- Orally available drug candidate.
- Lead indication in the treatment of cocaine use disorder (CUD).
- Also being researched for the treatment of alcohol use disorder (AUD), opioid use disorder (OUD), and polysubstance use disorder (PUD).
- A Phase 1 study of TMP-301 in healthy volunteers is expected to begin in Q1 2023.